Methods and materials for assessing prostate cancer therapies

Details Methods and materials for assessing prostate cancer therapies Methods and materials for assessing prostate cancer therapies

C - Chemistry, Metallurgy

12

Q

C12Q 1/68 (2006.01) A01N 43/04 (2006.01) A61K 31/70 (2006.01)

Patent

CA 2550447

Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest (2-5 fold) increase in androgen receptor (AR) mRNA was the only expression change consistently associated with developing resistance to antiandrogen therapy. Increased levels of AR confer resistance to anti- androgens by amplifying signal output from low levels of residual ligand and altering the normal response to antagonists. This invention provides cell based assays for use in the examination of new therapeutic modalities and provides insight toward the design of novel antiandrogens.

En établissant, au moyen de micro-réseaux, le profil de modèles de xénogreffes de cancers de la prostate isogéniques, on a trouvé qu'une faible augmentation (2-5 fois) de l'ARNm du récepteur d'androgène (AR) était la seule modification d'expression associée de façon constante au développement de la résistance à la thérapie par anti-androgènes. Des taux élevés de récepteur d'androgène (AR) confèrent une résistance aux anti-androgènes par amplification du signal émis à partir de faibles taux de ligand résiduel et par modification de la réponse normale aux antagonistes. L'invention concerne des analyses fondées sur les cellules à utiliser lors de l'examen de nouvelles modalités thérapeutiques et donne des idées pour la conception de nouveaux anti-androgènes.

Affiliated with

Also associated with

Rating

Methods and materials for assessing prostate cancer therapies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and materials for assessing prostate cancer therapies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and materials for assessing prostate cancer therapies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1915524